FR2891830B1 - Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale - Google Patents

Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale

Info

Publication number
FR2891830B1
FR2891830B1 FR0510289A FR0510289A FR2891830B1 FR 2891830 B1 FR2891830 B1 FR 2891830B1 FR 0510289 A FR0510289 A FR 0510289A FR 0510289 A FR0510289 A FR 0510289A FR 2891830 B1 FR2891830 B1 FR 2891830B1
Authority
FR
France
Prior art keywords
medical imaging
metal complexes
aminoalcohol compounds
short
short aminoalcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0510289A
Other languages
English (en)
Other versions
FR2891830A1 (fr
Inventor
Marc Port
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Original Assignee
Guerbet SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0510289A priority Critical patent/FR2891830B1/fr
Application filed by Guerbet SA filed Critical Guerbet SA
Priority to KR1020147009046A priority patent/KR101440761B1/ko
Priority to CA2625207A priority patent/CA2625207C/fr
Priority to CA2625196A priority patent/CA2625196C/fr
Priority to DK06807100.0T priority patent/DK1931673T3/da
Priority to PL06807100T priority patent/PL1931673T3/pl
Priority to ES12153144.6T priority patent/ES2519369T3/es
Priority to KR1020087010991A priority patent/KR20080080495A/ko
Priority to CN2006800416152A priority patent/CN101305006B/zh
Priority to PCT/EP2006/067211 priority patent/WO2007042504A2/fr
Priority to US12/083,269 priority patent/US8926945B2/en
Priority to ES06807100T priority patent/ES2390092T3/es
Priority to PT06807100T priority patent/PT1931673E/pt
Priority to CN201310087412.9A priority patent/CN103224495B/zh
Priority to BRPI0617151A priority patent/BRPI0617151B8/pt
Priority to JP2008534029A priority patent/JP5317270B2/ja
Priority to JP2008534028A priority patent/JP5368099B2/ja
Priority to EP06807097.8A priority patent/EP1940841B9/fr
Priority to PCT/EP2006/067214 priority patent/WO2007042506A1/fr
Priority to EP06807100A priority patent/EP1931673B1/fr
Priority to EP12153144.6A priority patent/EP2457914B1/fr
Priority to US12/083,092 priority patent/US8114863B2/en
Publication of FR2891830A1 publication Critical patent/FR2891830A1/fr
Publication of FR2891830B1 publication Critical patent/FR2891830B1/fr
Application granted granted Critical
Priority to US13/205,352 priority patent/US8986650B2/en
Priority to JP2013105720A priority patent/JP5731572B2/ja
Priority to JP2013107700A priority patent/JP5706926B2/ja
Priority to FR24C1006C priority patent/FR24C1006I1/fr
Priority to NL301259C priority patent/NL301259I2/nl
Priority to FIC20240003C priority patent/FIC20240003I1/fi
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/05—Mono-, di- or tri-ethylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR0510289A 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale Active FR2891830B1 (fr)

Priority Applications (28)

Application Number Priority Date Filing Date Title
FR0510289A FR2891830B1 (fr) 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
JP2008534028A JP5368099B2 (ja) 2005-10-07 2006-10-09 ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
CA2625196A CA2625196C (fr) 2005-10-07 2006-10-09 Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
DK06807100.0T DK1931673T3 (da) 2005-10-07 2006-10-09 Forbindelser, der omfatter korte aminoalkoholkæder og metalkomplekser, til medicinsk billeddannelse
PL06807100T PL1931673T3 (pl) 2005-10-07 2006-10-09 Związki zawierające krótkie łańcuchy aminoalkoholowe i kompleksy metali do obrazowania medycznego
ES12153144.6T ES2519369T3 (es) 2005-10-07 2006-10-09 Compuestos que comprenden cadenas de aminoalcohol cortas y complejos metálicos para la obtención de imágenes médicas
EP06807097.8A EP1940841B9 (fr) 2005-10-07 2006-10-09 Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
CN2006800416152A CN101305006B (zh) 2005-10-07 2006-10-09 含有短氨基醇链的化合物和用于医学成像的金属络合物
PCT/EP2006/067211 WO2007042504A2 (fr) 2005-10-07 2006-10-09 Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US12/083,269 US8926945B2 (en) 2005-10-07 2006-10-09 Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
ES06807100T ES2390092T3 (es) 2005-10-07 2006-10-09 Compuestos que comprenden cadenas de aminoalcohol cortas y complejos metálicos para la obtención de imágenes médicas
CA2625207A CA2625207C (fr) 2005-10-07 2006-10-09 Composes comprenant des chaines aminoalcool courtes et des complexes metalliques en imagerie medicale
CN201310087412.9A CN103224495B (zh) 2005-10-07 2006-10-09 含有短氨基醇链的化合物和用于医学成像的金属络合物
BRPI0617151A BRPI0617151B8 (pt) 2005-10-07 2006-10-09 composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico
KR1020147009046A KR101440761B1 (ko) 2005-10-07 2006-10-09 의학 영상용 짧은 아미노알코올 사슬과 금속착물을 포함하는 화합물
JP2008534029A JP5317270B2 (ja) 2005-10-07 2006-10-09 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物
KR1020087010991A KR20080080495A (ko) 2005-10-07 2006-10-09 의학 영상용 짧은 아미노알코올 사슬과 금속착물을포함하는 화합물
PCT/EP2006/067214 WO2007042506A1 (fr) 2005-10-07 2006-10-09 Composés comprenant des chaînes aminoalcool courtes et des complexes métalliques en imagerie médicale
EP06807100A EP1931673B1 (fr) 2005-10-07 2006-10-09 Composés comprenant des chaînes aminoalcool courtes et des complexes métalliques en imagerie médicale
EP12153144.6A EP2457914B1 (fr) 2005-10-07 2006-10-09 Composés comprenant des chaînes d'amino-alcool courtes et des complexes métalliques pour l'imagerie médicale
US12/083,092 US8114863B2 (en) 2005-10-07 2006-10-09 Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
PT06807100T PT1931673E (pt) 2005-10-07 2006-10-09 Compostos que compreendem cadeias de aminoálcoois e complexos metálicos para imagiologia médica
US13/205,352 US8986650B2 (en) 2005-10-07 2011-08-08 Complex folate-NOTA-Ga68
JP2013105720A JP5731572B2 (ja) 2005-10-07 2013-05-20 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物
JP2013107700A JP5706926B2 (ja) 2005-10-07 2013-05-22 ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
FR24C1006C FR24C1006I1 (fr) 2005-10-07 2024-02-19 Composes comprenant des chaines aminoalcool courtes et des complexes metalliques en imagerie medicale
NL301259C NL301259I2 (nl) 2005-10-07 2024-02-21 Gadopiclenol
FIC20240003C FIC20240003I1 (fi) 2005-10-07 2024-02-26 Gadopiklenoli

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0510289A FR2891830B1 (fr) 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale

Publications (2)

Publication Number Publication Date
FR2891830A1 FR2891830A1 (fr) 2007-04-13
FR2891830B1 true FR2891830B1 (fr) 2011-06-24

Family

ID=36636179

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0510289A Active FR2891830B1 (fr) 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
FR24C1006C Active FR24C1006I1 (fr) 2005-10-07 2024-02-19 Composes comprenant des chaines aminoalcool courtes et des complexes metalliques en imagerie medicale

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR24C1006C Active FR24C1006I1 (fr) 2005-10-07 2024-02-19 Composes comprenant des chaines aminoalcool courtes et des complexes metalliques en imagerie medicale

Country Status (15)

Country Link
US (1) US8114863B2 (fr)
EP (2) EP2457914B1 (fr)
JP (2) JP5317270B2 (fr)
KR (2) KR101440761B1 (fr)
CN (2) CN103224495B (fr)
BR (1) BRPI0617151B8 (fr)
CA (1) CA2625207C (fr)
DK (1) DK1931673T3 (fr)
ES (2) ES2390092T3 (fr)
FI (1) FIC20240003I1 (fr)
FR (2) FR2891830B1 (fr)
NL (1) NL301259I2 (fr)
PL (1) PL1931673T3 (fr)
PT (1) PT1931673E (fr)
WO (1) WO2007042506A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
FR2914303A1 (fr) * 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
US8378134B2 (en) 2009-09-30 2013-02-19 General Electric Company Hydroxylated contrast enhancement agents
US20110077396A1 (en) * 2009-09-30 2011-03-31 General Electric Company Intermediates for hydroxylated contrast enhancement agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
AU2012296937B2 (en) * 2011-08-17 2017-10-12 Merck & Cie Folate conjugates of albumin-binding entities
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
PL2988756T5 (pl) * 2013-04-26 2022-09-26 Guerbet Formulacja środka kontrastowego i powiązany sposób jego wytwarzania
CN103467504B (zh) * 2013-09-23 2015-06-24 武汉工程大学 18f-氟标记卟啉-异氮杂茚自由基配合物及合成方法
CN104485193B (zh) * 2014-12-29 2016-11-02 广西师范大学 一种以酰腙类希夫碱为配体构筑的磁性材料及其制备方法
EP3101012A1 (fr) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
HRP20221451T1 (hr) * 2015-12-10 2023-02-17 Bracco Imaging Spa Dimerna kontrastna sredstva
EP3223181B1 (fr) 2016-03-24 2019-12-18 Sofradim Production Système et procédé de génération d'un modèle et de simulation d'un effet sur un site de réparation chirurgicale
WO2017178301A1 (fr) * 2016-04-13 2017-10-19 Bracco Imaging Spa Agents de contraste
GB201610738D0 (en) * 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
ES2814555T3 (es) 2016-11-28 2021-03-29 Bayer Pharma AG Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética
WO2018115314A1 (fr) * 2016-12-21 2018-06-28 Ge Healthcare As Composés de chélate de manganèse à base de tétraazabicyclo-macrocycle appropriés en tant qu'agents d'imagerie irm
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
US11110186B2 (en) 2017-12-20 2021-09-07 General Electric Company Anionic chelate compounds
ES2938015T3 (es) 2018-08-06 2023-04-03 Bracco Imaging Spa Agentes de contraste basados en PCTA que comprenden gadolinio
BR112021007707A2 (pt) 2018-11-23 2021-07-27 Bayer Aktiengesellschaft formulação de meios de contraste e processo de preparação da mesma
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
JP2023533810A (ja) 2020-07-16 2023-08-04 ゲルベ ２－ブロモグルタル酸ジエステルを合成するための方法
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
EP4182314A1 (fr) 2020-07-17 2023-05-24 Guerbet Procede de preparation d'un ligand chelateur derive de pcta
CN114105983B (zh) * 2021-11-09 2023-08-11 国科温州研究院(温州生物材料与工程研究所) 手性1,4,7,10-四氮杂-2,6-吡啶环蕃衍生物及其金属螯合物的制备和应用
WO2024049087A1 (fr) * 2022-09-01 2024-03-07 주식회사 테라노큐어 Nouveau composé et agent de contraste irm le comprenant

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135748A (en) 1960-05-27 1964-06-02 Little Inc A Heterocyclic substituted carbodhmides and method of preparation
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
DE3825040A1 (de) * 1988-07-20 1990-01-25 Schering Ag 5- oder 6-ring- enthaltende makrocyclische polyaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4001655A1 (de) * 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5554748A (en) 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
EP0579802B1 (fr) 1991-12-10 2000-04-26 The Dow Chemical Company Complexes et conjugues a base d'acides bicyclopolyazamacrocyclocarboxylique, leur preparation et utilisation et tant qu'agents de contraste
PT661279E (pt) 1993-12-30 2001-06-29 Guerbet Sa Ligandos poliaminados complexos metalicos processo de preparacao aplicacoes em diagnostico e terapeuticas
EP0971747B1 (fr) 1996-10-28 2005-12-28 Amersham Health AS Agents de contraste
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6071490A (en) 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
FR2793795B1 (fr) * 1999-05-21 2001-08-03 Guerbet Sa Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale
FR2794744B1 (fr) * 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
EP1203026A4 (fr) 1999-07-29 2005-03-16 Dyax Corp Fractions se liant la fibrine
WO2001052900A2 (fr) * 2000-01-21 2001-07-26 Mallinckrodt Inc. Nouveaux chelateurs d'acides amines a protection orthogonale pour des applications biomedicales
US6450956B1 (en) 2000-11-06 2002-09-17 Siemens Corporate Research, Inc. System and method for treatment and outcome measurement analysis
ITMI20011518A1 (it) * 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
FR2836916B1 (fr) * 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
WO2005001415A2 (fr) 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Isomeres optiquement purs et enrichis de ligands chelateurs et agents de contraste
FR2856689A1 (fr) 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
CA2526556C (fr) 2003-07-24 2012-09-25 Bracco Imaging S.P.A. Compositions radiopharmaceutiques stables et methodes pour leur preparation
US20050136003A1 (en) 2003-10-31 2005-06-23 Casebier David S. Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use
GB0326546D0 (en) 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
WO2005049095A2 (fr) 2003-11-24 2005-06-02 Amersham Health As Agent de contraste
JP2007516288A (ja) 2003-12-23 2007-06-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 金属キレート剤として有用な新規化合物
ATE430146T1 (de) 2004-07-02 2009-05-15 Bracco Imaging Spa Kontrastmittel mit hoher relaxivität zur verwendung in der magnetresonanzbilddarstellung (mri), enthaltend eine chelatbildende gruppe mit polyhydroxylierten substituenten
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale

Also Published As

Publication number Publication date
EP1931673A1 (fr) 2008-06-18
CN103224495A (zh) 2013-07-31
FIC20240003I1 (fi) 2024-02-26
JP5731572B2 (ja) 2015-06-10
PT1931673E (pt) 2012-09-24
EP2457914B1 (fr) 2014-08-06
FR2891830A1 (fr) 2007-04-13
DK1931673T3 (da) 2012-10-08
JP5317270B2 (ja) 2013-10-16
CN101305006B (zh) 2013-04-24
JP2013209400A (ja) 2013-10-10
KR101440761B1 (ko) 2014-09-17
US20090169479A1 (en) 2009-07-02
WO2007042506A1 (fr) 2007-04-19
CN103224495B (zh) 2015-07-15
FR24C1006I1 (fr) 2024-04-19
ES2519369T3 (es) 2014-11-06
CA2625207A1 (fr) 2007-04-19
NL301259I2 (nl) 2024-03-25
KR20080080495A (ko) 2008-09-04
BRPI0617151B8 (pt) 2021-07-27
JP2009513574A (ja) 2009-04-02
CA2625207C (fr) 2014-05-13
EP2457914A1 (fr) 2012-05-30
KR20140060565A (ko) 2014-05-20
EP1931673B1 (fr) 2012-08-29
BRPI0617151A2 (pt) 2011-07-12
PL1931673T3 (pl) 2012-11-30
BRPI0617151B1 (pt) 2020-08-11
CN101305006A (zh) 2008-11-12
US8114863B2 (en) 2012-02-14
ES2390092T3 (es) 2012-11-06

Similar Documents

Publication Publication Date Title
FR2891830B1 (fr) Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
EP1809601A4 (fr) Composes destines a la maladie d'alzheimer
HK1206104A1 (en) Confocal microscope for imaging of selected locations of the body of a patient
IL188165A0 (en) Method for the diagnosis of alzheimer's disease
GB2427362B (en) Imaging catheter
FR2857200B1 (fr) Processeur video pour l'endoscopie
EP2011513A4 (fr) Agents thérapeutiques employés dans le cadre de la maladie d'alzheimer et du cancer
IL175667A0 (en) Novel imaging agents
FR2862861B1 (fr) Positionnement d'objets pour l'acquisition d'images
EE200300216A (et) Radiofarmatseutilised ained Alzheimeri tõve diagnoosimiseks
FR2872963B1 (fr) Piece d'extremite femelle
EP1450863A4 (fr) Procedes d'imagerie vasculaire comprenant l'utilisation d'agents de contraste nanoparticulaires
ZA200603178B (en) Quick test for the diagnosis of Alzheimer's disease
AU2003209301A8 (en) Treatments for neurotoxicity in alzheimer's disease
PL2446869T3 (pl) Element zapięcia pieluchy
GB2415896B (en) An angler's seat box
FR2882248B1 (fr) Porcede et systeme pour aider au guidage d'un outil a usage medical
GB0414894D0 (en) Biomarkers of alzheimer's disease
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
ZA200711163B (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
GB0510474D0 (en) Q's vaginometer
FR2837285B1 (fr) Pack d'imagerie ultrasonore
FR2882546B1 (fr) Dispositif d'ouverture d'un embaallage sous forme de portion triangulaire
HUP0600409A3 (en) Izatin and it's derivatives for use as a medicine
GB0410101D0 (en) Parkinson's disease

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19